An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Single Dose Pharmacokinetics of the MEK Inhibitor, GSK1120212, in Subjects With Solid Tumors.

Trial Profile

An Open-Label, Two-Period, Randomized, Crossover Study to Evaluate the Effect of Food on the Single Dose Pharmacokinetics of the MEK Inhibitor, GSK1120212, in Subjects With Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Trametinib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 25 Jul 2013 Results published in the Journal of Clinical Pharmacology.
    • 09 Mar 2013 Results presented at the 114th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 04 Apr 2012 Actual patient number 24 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top